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1  | INTRODUC TION
The mammalian immune system has evolved to efficiently ward off a 
panoply of external threats while minimizing, in most cases, self‐in‐
flicted damage. Many infective organisms, however, have themselves 
evolved sophisticated strategies to circumvent and overcome the 
immune response of the host. It is in this fascinating interplay that 
we have come to recognize that some parasites can directly manipu‐
late and suppress inflammatory responses to an extent that actually 
protects the host from immunological disorders such as allergy, au‐
toimmunity and the metabolic syndrome.1‐4 A major question then 
arises as whether the disappearance of parasites from most of the 
industrialized countries is causally responsible for the relentless rise 
in inflammatory disorders such as asthma,5 inflammatory bowel dis‐
ease 6 and type 1 diabetes 7 over the course of the 20th century.8
The phenomenon of parasite‐mediated immune suppression was 
first noted in the 1960s by Greenwood as a notably low prevalence 
of autoimmune conditions in Nigerian hospital admission cohorts 9; 
this prompted him to study animal models in which malaria infection 
abated autoimmunity 10; the “Hygiene Hypothesis” as such was inde‐
pendently postulated by Strachan reflecting on family data in which 
younger members of larger sibships exhibited lower allergy levels, 
attributed to greater exposure to micro‐organisms in infancy.11,12 In 
this era, anecdotal reports also appeared in which, for example, in‐
fection with the hookworm helminth Necator americanus abolished 
hay fever in a British subject.13
Hookworms are among the highly prevalent group of helminth 
(metazoan, worm) parasites which will be the primary focus of this 
article. Helminths remain extraordinarily prevalent in lower‐income 
countries, with over 2 billion people infected.14 Unlike most micro‐
organisms and unicellular protozoa, helminths cannot outrun the im‐
mune system by rapid growth and instead rely on down‐modulation 
of host immunity. In some cases, infections are asymptomatic and 
the host appears to be immunologically tolerant of the parasite 15; in 
others, regulation is not so well‐ordered and inflammatory responses 
to the parasite generate severe pathology of tissues such as the liver 
16 or lymphatic system.17 Whether the “tolerant” state may confer 
benefits such as reduced allergy is a topic of current debate, but even 
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Abstract
There is increasing interest in helminth parasite modulation of the immune system, 
both from the fundamental perspective of the “arms race” between host and para‐
site, and equally importantly, to understand if parasites offer new pathways to abate 
and control untoward immune responses in humans. This article reviews the epide‐
miological and experimental evidence for parasite down‐regulation of host immunity 
and immunopathology, in allergy and other immune disorders, and recent progress 
towards defining the mechanisms and molecular mediators which parasites exploit 
in order to modulate their host. Among these are novel products that interfere with 
epithelial cell alarmins, dendritic cell activation, macrophage function and T‐cell re‐
sponsiveness through the promotion of an immunoregulatory environment. These 
modulatory effects assist parasites to establish and survive, while dampening im‐
mune reactivity to allergens, autoantigens and microbiome determinants.
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2  |     MAIZELS
if so there are clearly also disbenefits, in respect of compromised 
responses to vaccination 18 and certain microbial infections.19,20
2  | INSIGHTS FROM HUMAN PAR A SITE 
INFEC TIONS
A long‐standing theme in human helminth infections has been the 
paucity of parasite‐specific immune responses, manifest, for exam‐
ple, as inability of effector T cells to proliferate or produce inflamma‐
tory cytokines when stimulated with parasite antigens, considered 
to be a form of immunological tolerance.21,22 Established helminth 
infections are also characterized by highly elevated IgG4 levels,23,24 
as also observed in desensitized allergic patients outside parasite‐
endemic environments.25 Interestingly, IgG4 expression in human 
helminth infections is linked to the regulatory network, through 
IL‐10 production and other down‐modulatory signals.26
Immunological tolerance to parasites has been more closely at‐
tributed to regulatory cells in a number of settings.27‐30 Both par‐
asite‐specific and bystander immune responses can be restored in 
vitro by depletion of T regs,29 and in vivo by anthelmintic chemo‐
therapy.31,32 As discussed below, parasites are able to directly pro‐
mote or induce Tregs.33 In addition, Bregs and immunosuppressive 
macrophages have been implicated in a number of studies on hel‐
minth parasite infections.34,35
3  | HELMINTH PAR A SITES AND ALLERGY
A landmark study was published in 2000 by the Yazdanbakhsh 
group,36 measuring skin prick test (SPT) reactivity (atopy) to house 
dust mite allergen; Schistosoma‐infected children were significantly 
less prone to allergy, while in the small proportion who retained 
demonstrable skin test reactivity, peripheral blood T cells failed to 
mount an IL‐10 response to parasite antigens. Hence, the links were 
made firstly between helminths and diminished allergy, and sec‐
ondly between the parasite infection and, in most children, an im‐
munoregulatory cytokine.
A diversity of subsequent studies, in different settings of in‐
fection with a variety of helminth species, has broadly supported a 
negative association with allergic reactivity 37‐40; while there have 
also been reports that could not establish a significant influence of 
helminth infection,41 it has been argued that protection from allergy 
is likely to require a threshold intensity and duration of infection and 
may vary from parasite species to species.42,43 Most recently, the 
original observations have been confirmed in a much larger study of 
>2000 neonates over 3‐5 years in Ecuador, in which one‐third of the 
cohort contracted helminth infections but overall developed signifi‐
cantly less asthma and wheeze.44
It is important to note that not all studies have reported negative 
associations between infection and allergy. Indeed, there are many 
instances of sensitization and allergic reactions to parasites, partic‐
ularly where zoonotic transmission occurs and the human is not the 
definitive host.45,46 Examples are Toxocara canis, a canine nematode 
in which larval forms migrate through tissues of humans who have 
accidently ingested eggs,47 and Anisakis simplex, a marine nematode 
which can be acquired by eating undercooked fish.48 However, in 
both cases these are “dead‐end” infections in which parasites are 
maladapted to the human and so fail either to complete their life 
cycle or down‐modulate host immune reactivity.
In contrast, the prevalent human helminth parasites are very 
effective at ensuring both transmission and immune modulation. 
In further key studies, a causal link between parasitism and down‐
modulated allergy was established by evaluating the consequences 
of anthelminthic drug treatment to expel parasites. In another 
Gabon study, infants cleared of intestinal nematode parasites more 
frequently converted to an atopic state of SPT reactivity, than the 
comparator cohort of untreated children.49
4  | BROAD SPEC TRUM OF IMMUNE 
MODUL ATION BY HELMINTHS
Following work with allergy in helminth‐infected children, a remark‐
able study was reported by Correale and colleagues on adult multi‐
ple sclerosis (MS) patients who had adventitiously acquired intestinal 
helminth infections; 12 such individuals were followed but remained 
in remission while uninfected subjects with similar disease scores 
at the initial time point experienced repeated relapses and exacer‐
bations.50 The infected patients showed enhanced IL‐10 and TGF‐β 
production by peripheral blood mononuclear cells 50 and increased 
regulatory B‐cell numbers.34 In a subsequent follow‐up, these au‐
thors treated 4 infected patients to clear the helminth parasites, but 
reported diminution in immunosuppressive cytokines together with 
an intensification of disease scores.51
In a third setting, in India, a reciprocal relationship was found 
between intensity of infection with the mosquito‐borne filarial nem‐
atode Wuchereria bancrofti and the incidence of type 1 diabetes,52 
although in this case no causality could be established. Finally, in 
Zimbabwe the levels of anti‐nuclear antibody (ABA) were measured 
in S haematobium‐infected and S haematobium‐uninfected individu‐
als, as an early precursor (but not predictor) of autoimmune reactiv‐
ity; anti‐ANA titres were significantly lower in the infected cohort, 
but increased following treatment with the anti‐schistosomal drug 
praziquantel.53
5  | LE ARNING FROM ANIMAL MODEL S
Many animal models of helminth infection have echoed and expanded 
on the observations of immune modulation in humans. For example, 
type 1 diabetes in the NOD mouse model is potently inhibited by 
infections such as Schistosoma mansoni 54 and Heligmosomoides po‐
lygyrus 55‐57 as also are other autoimmune disorders such as EAE in 
models of multiple sclerosis,58,59 as well as experimental colitis in an‐
imals.60 Moreover, there are multiple reports of helminth infections 
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suppressing graft rejection and prolonging allograft survival,61 and 
emerging evidence is that these parasites counteract metabolic dis‐
orders in models of obesity.62 Some of these effects—for example, 
the ability of the liver fluke Fasciola hepatica and eggs from S mansoni 
to suppress Th1/Th17‐mediated autoimmunity—have been attrib‐
uted to immune diversion towards a nonpathogenic Th2 response 
63,64; however, in allergy and other models, a more subtle redirection 
of immunity to favour a regulatory environment has been demon‐
strated. Fuller accounts of these findings have been published re‐
cently in major review articles.65‐67
It is perhaps in the context of allergy that the principles and 
mechanisms of helminth down‐modulation have been most clearly 
established and shown to operate at several levels against both in‐
nate and adaptive immunities. Multiple helminth species can, when 
introduced in to mice, forestall the development of allergic inflam‐
mation,68,69 including H polygyrus 70‐72 and S mansoni 43,73,74 as well 
as the filarial parasite Litomosoides sigmodontis.75 Mechanistically, 
protection can be transferred from infected donors to uninfected 
recipients with CD4+ Tregs 71 and abolished by Treg depletion with 
anti‐CD25 antibody 73 or genetic ablation.74 However, B‐cell trans‐
fer experiments have also successfully conferred protection against 
allergy, consistent with a “Breg” population stimulated by helminth 
infections,76‐78 albeit in 1 system functioning through activation of 
Treg counterparts.76
6  | THE HYGIENE HYPOTHESIS TODAY
Many authors have elaborated, adapted and broadened Strachan's 
original postulate, in particular to encompass parasites as well as 
microbes, and to incorporate regulatory cell networks which were 
poorly defined in the 1980s. In addition, a gamut of environmental 
influences has been invoked, from the “old friends” of mycobacte‐
ria,79 to specific commensal microbes, and through to farm dust and 
diet in a continuum, each of which can clearly exert major influences 
on development of immunity. Importantly, the immune system is 
conceived as an integrated whole in which all disorders including au‐
toimmunity and inflammatory bowel diseases may be concomitantly 
regulated.80
Two “hygiene hypotheses” have been formulated that are not 
mutually exclusive but involve conceptually distinct mechanisms 
(Figure 1). Firstly, there is the idea that in early life, the immune 
system is conditioned or imprinted by its environment, such that a 
higher infection experience will promote regulation; alternatively 
that the presence of parasites (or other modulatory organisms such 
as certain commensal bacteria) sufficiently inhibits the mature im‐
mune response to dampen autoimmunity etc81 In related argument, 
observations on human allergies primarily reflect sensitization 
(through SPT) rather than clinical allergy,82 suggesting that the pri‐
mary effect of helminths is in determining the tonal “set‐point” of the 
immune system rather than the specific response to any 1 antigen.
The second interpretation of the hygiene hypothesis is that the 
fully formed immune system, in school‐aged children and adults, can 
be recalibrated by exposure to infectious agents, whether common 
viral and bacterial microbes, or helminth parasites.81 This notion un‐
derpins the approach of using live organisms, or products from those 
organisms, as new therapies for inflammatory diseases, as discussed 
below, and is supported by nearly all studies in experimental animals, 
in which the effects of parasite infection are tested on the inflamma‐
tory reactions of adult mice.
F I G U R E  1   Early and late acting influences on the immune system which may underpin the Hygiene Hypothesis. Maternal infection 
status can influence the development of allergy in offspring, with further early‐life effects resulting from neonatal infections that may either 
promote tolerance or sensitize the newborn host. Changes in diet at weaning and the use of antibiotics in infancy can alter the microbiome, 
with potential lifelong consequences. In later life, the mature immune system may also be modulated by infectious agents, particularly those 
such as helminths which exert immunosuppressive effects and activate the immune regulatory network. Thus, prevention of allergy may 
require intervention in the maternal and early‐life environment, while therapy can exploit helminth products to dampen established allergic 
diseases
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7  | IMPRINTING IN E ARLY LIFE
An important issue arising from the alternative formulations of the 
hygiene hypothesis is how early‐life, and indeed prenatal, exposure 
to helminths and helminth antigens may influence the immunological 
“set‐point” that may have lifelong consequences. For example, infec‐
tion with the whipworm Trichuris trichiura during the first 5 years of life 
in Brazilian children was reported to significantly reduce incidence of 
allergy in their later years, even in children no longer carrying the para‐
site infection.83 Similarly, in the mouse model of Schistosoma mansoni 
infection, pups born to chronically infected dams in the “regulatory” 
phase of infection showed significantly reduced airway responses to 
ovalbumin challenge.84,85
The impact of gestational helminth exposure and immune devel‐
opment is also fascinating in the human setting.86 In Uganda, ma‐
ternal hookworm infection resulted in reduced allergy (eczema) in 
infants for up to 5 years of age, as indeed did infection with either 
hookworm or T trichiura when analysing the children alone.87 In an 
earlier Ecuador study, maternal helminth infection appeared to have 
little influence on overt allergy, although SPT reactions were signifi‐
cantly reduced in the offspring of these mothers.88 More recently, a 
study from the same country reported that while maternal helminth 
infection increased risk of infants developing allergy (wheeze, skin 
reactivity), within the infant cohort itself, neonatal helminth infec‐
tion reduced allergies.44
8  | HELMINTHS AND THE MICROBIOTA
Intestinal helminths share their niche with the commensal micro‐
biome, principally bacteria but also fungi and viruses.89‐91 In addi‐
tion, there is microbial colonization of the airways which has major 
implications for the immune status of the respiratory tract.92 With 
increasing recognition of how microbial exposure first shapes the 
developing immune system, and then interacts with the host to de‐
velop a healthy homeostasis, many questions have been raised about 
helminth effects on the microbiome, and whether immunoregulation 
in parasite infection acts indirectly through changes in the microbial 
population.93,94 Helminth infections can clearly alter the microbi‐
ome in both humans and animals 95‐97; for example in the murine 
model of H polygyrus, infection favoured expansion of small intes‐
tinal Lactobacillus 98,99; interestingly, mice pre‐exposed to the same 
Lactobacillus were more susceptible to worm infection, both organ‐
isms expanding the regulatory T‐cell compartment of the host.99 
However, the same helminth can also allow a pathobiont, Salmonella 
typhimurium, to expand with deleterious effects.100 Hence, the influ‐
ence of helminths on the microbiome is highly context‐dependent 
with correspondingly varied outcomes.
A central question has been whether, in the model systems in 
which helminths down‐modulate allergy to bystander antigens, par‐
asites act indirectly by altering the intestinal microbiome.101 This 
was also addressed in the H polygyrus model, in which amelioration 
of airway allergic inflammation was attributed to the outgrowth of 
Clostridium species in the large intestine, as the source of short‐
chain fatty acids which promote regulatory T‐cell activity through 
the GPR41 receptor.102 As these authors note, however, this study 
does not exclude the likelihood that helminths also directly suppress 
immune reactions independently of the microbiota, as evidenced 
by increasing definition of allergy‐suppressing proteins released by 
many parasites, among them H polygyrus itself.67,103
In both the intestinal tract and the airways, barrier integrity can 
be physically compromised by helminth parasites, which can initiate 
a type 2 proto‐allergic response (Figure 2). Studies on barrier func‐
tion in helminth infections of the intestinal tract have documented 
increased epithelial permeability,104 which contributes to the “weep‐
and‐sweep” mechanism for parasite clearance. Although this is in 
part dependent on type 2 cytokines, it is interesting to note that 
helminth products can themselves induce increased permeability,105 
suggesting that parasite immunomodulatory molecules may thereby 
gain better access to host tissues, and providing a pathway through 
which intestinal helminths may exert systemic effects on the host 
immune system.
9  | WHAT ABOUT HELMINTH THER APY?
Over the past decade, interest has developed in deliberate hel‐
minth parasite infection as a therapy for inflammatory disorders,106 
sparked by promising trials in which Crohn's disease and ulcerative 
colitis patients benefitted from infection with the pig whipworm, 
Trichuris suis.107‐109 Other authors reported a case of a UC patient 
who deliberately self‐infected with the whipworm T trichiura leading 
to reduction in inflammatory marker expression and overall remis‐
sion of disease.110 In larger trials, however, neither the whipworm 
nor other tests with the human hookworm N americanus demon‐
strated significant protection in IBD or indeed in a number of other 
conditions including asthma,111 rhinitis,112 multiple sclerosis 113 and 
coeliac disease.114 Thus, despite accounts of benefits to some indi‐
vidual patients, and a general trend towards subtle improvements 
in patients, there is currently no compelling study that supports 
deliberate helminth infection as a standard counter‐inflammatory 
therapy.115,116
10  | THE ALTERNATIVE—PAR A SITE 
MOLECULES AND MECHANISMS
With live helminth infections proving less than universally effective, 
there is increasing priority given to dissecting helminth‐driven regu‐
latory pathways and finding mediators from parasites that engage 
these pathways.69,117 Such helminth‐derived molecules, in synthetic 
form, could reproduce the anti‐inflammatory properties of live para‐
sites without exposing patients to the detrimental effects of infec‐
tion. A growing number of studies have highlighted key parasite 
products that directly interact with the host immune system and 
uncovered new pathways by which immune modulation occurs in 
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parasite infections 67,118‐121 (Figure 3). A selection of parasite mol‐
ecules of particular interest in control of inflammation is discussed 
below, and the reader is referred to recent more comprehensive re‐
views for further information.67,122
Parasites interfere with each phase of the immune response 
from the initial recognition and activation signals, through to the 
final stage of effector cells attempting to resolve infection. Even the 
very first steps of the response through epithelial cell alarmins are 
directly targetted. This is well illustrated by recent work describing 
Hp‐ARI (Alarmin Release Inhibitor) from H polygyrus. It was first es‐
tablished that proteins secreted by this parasite were able to block 
the action of IL‐33, the initiator of type 2 immunity in the tissues, 
thereby preventing ILC2 activation and subsequent airway eosino‐
philia in response to Alternaria fungal allergens.123,124 Identification 
of the mediator involved revealed Hp‐ARI as bi‐functional protein 
which binds both active IL‐33 in fluid phase, and also nuclear DNA. 
As IL‐33 is normally held in the cell nucleus until cell stress or trauma 
triggers its release, Hp‐ARI reverses the process, capturing the 
F I G U R E  2   Pathways of allergic inflammation and helminth immune modulation. Helminths may penetrate and damage epithelial tissue, 
releasing parasite PAMPs (pathogen‐associated molecular patterns) and host DAMPs (damage‐associated molecular patterns). Type 2 
inflammation (coloured red) is initiated in response to DAMPs/PAMPs, together with antigen presentation by dendritic cells (DCs), to 
generate type 2 innate lymphoid cells (ILC2) and helper T cells (Th2). Type 2 lymphocytes induce allergic mediators including eosinophils 
and IgE from B cells. In the presence of an immunomodulatory helminth, a regulatory network is invoked (coloured green) and DCs may 
instead induce regulatory T cells (Tregs) that produce suppressive cytokines (IL‐10 and TGF‐beta). These act on B cells to switch to IgG4 
production, on macrophages to assume an anti‐inflammatory (M2) phenotype, and on effector Th2 cells to block activation and develop a 
state of tolerance. These pathways inhibit both helminth‐specific and bystander (eg allergen‐specific) reactivity, thereby creating a profound 
anti‐inflammatory effect
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F I G U R E  3   Illustration of pathways of immune interference by the model helminth parasite H polygyrus mediated by the excretory‐
secretory products (HES) and 2 newly defined components. One, Hp‐ARI, targets innate immunity by neutralizing IL‐33, thereby forestalling 
activation of ILC2, eosinophils and M2 macrophages.103 A second, TGM, activates the TGF‐β pathway to induce regulatory T cells 155; 
these suppress the adaptive Th2 arm of immunity, further inhibiting M2 macrophage induction and the differentiation of epithelial effector 
populations such as the goblet cells. In these ways, the parasite prevents both outcomes of the Th2 response, namely allergic inflammation 
and helminth expulsion
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alarmin cytokine and sequestering it within the nucleus, thus neu‐
tralizing its biological function in immunity.103 In vivo, Hp‐ARI effec‐
tively blocks the airway allergic reaction to Alternaria even if given 
24 hours in advance of the allergen challenge.103
11  | MODUL ATION OF MYELOID CELL S BY 
HELMINTH PRODUC TS
A broader picture emerges from studies on the activation and 
modulation of dendritic cells (DCs), which are targetted by multiple 
parasite products, many of which inhibit IL‐12 production and ex‐
pression of co‐stimulatory markers.125‐127 Schistosome eggs release 
the protein omega‐1 which downgrades DC protein synthesis, par‐
ticularly blocking IL‐12 production, and promoting the induction of 
a Th2 response.128,129 The same parasites secrete a small lipid mol‐
ecule, lyso‐phosphatidylserine, which drives a more regulatory DC 
phenotype through a TLR2 interaction.130 Another major modulator 
of DCs is the ES‐62 glycoprotein secreted by a rodent filarial para‐
site, Acanthocheilonema viteae, which acts at the intracellular level 
to bind and divert the MyD88 adapter protein required for TLR and 
IL‐33 signalling.131,132 The glycan moiety of ES‐62 is further substi‐
tuted with phosphorylcholine (PC) which is the active principle of 
the molecule; ES‐62 devoid of PC is no longer immunomodulatory, 
while PC‐substituted ovalbumin and small molecule mimics of PC are 
able to recapitulate its effects 133,134; hence, new drugs inspired by 
ES‐62 may prove as effective as the whole glycoprotein in ameliorat‐
ing conditions such as asthma 135 and rheumatoid arthritis.136
Other myeloid cell populations are also profoundly modulated by 
helminth products. Macrophages in particular play an essential role 
in the immune response to helminths and can mediate both protec‐
tive 137 and pathological consequences.138,139 A family of cysteine 
protease inhibitors are produced by filarial parasites, with the ability 
to block both conventional cathepsins, and also the asparaginyl en‐
dopeptidase required for antigen processing by human cells in vitro. 
One of these (Av‐Cystatin) has been further studied in mouse models 
and found to act through macrophages, resulting in them suppress‐
ing airway allergy in treated mice in an IL‐10‐dependent manner,140 
through the recruitment of IL‐10+CD4+ T cells.141 As with DCs, inter‐
ference with TLR activation is found by parasite products, for exam‐
ple the Fasciola hepatica cathepsin L1 enzyme which breaks down 
TLR3 in macrophages and prevents downstream signalling through 
TRIF,142 while another protein from the same parasite, FhHDM‐1, is 
able to interfere with both surface interactions with LPS, and inter‐
nal antigen processing and inflammasome activation.143,144
Macrophages in helminth infection adopt a characteristic alter‐
natively activated (or M2) phenotype,145 expressing high levels of 
arginase‐1 which by converting the amino acid substrate into polyam‐
ines and proline strongly favour tissue repair and wound healing. M2 
macrophage differentiation is stimulated by the cytokines IL‐4 and 
IL‐13, but can be further promoted in synergy with certain helminth 
products such as the macrophage migration inhibitory factor (MIF) 
homologues from the filarial parasite Brugia malayi.146 Furthermore, 
M2 macrophages play an essential role in metabolic homeostasis; 
hence, infection with Nippostrongylus brasiliensis indirectly counter‐
acts obesity, stimulating eosinophils which release IL‐4 and induce 
M2 differentiation.147 In a parallel development, the schistosome pro‐
tein omega‐1 has been found to ameliorate insulin resistance in mice 
through the IL‐33–dependent activation of M2 macrophages.148
12  | HELMINTH‐INDUCED REGUL ATORY  
T CELL S
Arguably, the most central feature of helminth infection is the 
promotion of regulatory T‐cell activity,33,149 and as discussed 
above, Treg expansion can also account for the inhibition of al‐
lergic responses in mouse models.71,150 Parasites have evolved 
multiple strategies to exploit the Treg pathway, including modu‐
lating DCs to drive Treg induction 151,152 and IL‐10 production.130 
In one recently reported example, hookworm Anti‐Inflammatory 
Protein (AIP)‐2 protein acts in mouse models through CD103+ DCs 
to expand Tregs; as a result, AIP‐2 administration can abate air‐
way allergic inflammation 152 as well as colitis induced by TNBS 
administration.153
While products such as AIP‐2 act indirectly on the host to gen‐
erate Tregs, some parasite molecules can do so directly without the 
need for intermediary DC populations.154 In this respect, the most 
remarkable is the TGF‐β mimic (TGM) from H polygyrus, which bear‐
ing no sequence similarity to mammalian TGF‐β, has convergently 
evolved to bind the same family of TGF‐β receptors, driving Smad 
phosphorylation and, in T cells, Foxp3 expression.155 While TGF‐β 
requires proteolytic processing from a longer preprotein, and re‐
lease from the extracellular integrin matrix before it gains activity, 
TGM is active as a newly synthesized full‐length protein. A further 
contrast is that TGFβ binds directly to the TGFβR‐II chain, which re‐
cruits and phosphorylates TGFβRI, while TGM binds strongly and 
independently to both receptor chains. As a consequence, TGM is 
a potent ligand for the TGFβ signalling pathway which can induce 
a higher level of Foxp3 expression in naive T cells.155 Thus, TGM 
represents a molecular pathway, which explains and underpins the 
observed ability of H polygyrus to induce and recruit Tregs in vivo, 
which are known to be required for parasite survival in the immu‐
nocompetent host.156 In mouse models, TGM proved to confer ex‐
tended survival of fully allogeneic skin grafts in mice, to a similar 
degree to infection with the parasite itself.155
A further illustration of how helminth interferes with the host 
cytokine network has recently been described through p43, the 
major secreted protein of Trichuris muris whipworms from mice. This 
product is able to bind host IL‐13, and through a separate throm‐
bospondin‐like binding site can sequester the cytokine within host 
extracellular matrix, preventing it from activating the type 2 immune 
response.157 As IL‐13 is a central player in allergic asthma 158 and 
closely homologous proteins are also elaborated by the human whip‐
worm T trichiura, this pathway is also likely to be important in allevi‐
ation of allergy by helminths.
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13  | CONCLUSION
Helminth parasites have co‐evolved with our immune system and 
are being revealed as storehouses of extraordinary immunological 
tools that manipulate every facet of immunity. The study of the im‐
mune response to helminths has illuminated many areas of common 
ground with allergy and other inflammatory settings. In particular, 
the cellular immunology of the response to helminth infection has 
revealed critical new populations such as the type 2 innate lymphoid 
cell 159 and the intestinal epithelial tuft cell,160,161 while reinterpret‐
ing the functions of subsets such as M2 macrophages,162 mast cells 
and basophils.163,164
With our growing understanding of the molecular strategies of 
helminth parasites, we can now begin to see how they may inspire 
future therapies against inflammatory diseases. Defined parasite 
products target specific pathways, receptors and cell populations 
which require to be controlled in particular disease conditions, as 
in the examples of an inhibitor of IL‐33, the alarmin which is closely 
linked to asthma in humans. In addition, broadly acting mediators 
such as those driving regulatory cell populations hold promise for 
recalibrating the over‐active immune system in allergic disease.
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